Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 16 Show results per page	View Search Criteria \| Help With Results


1.		Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Other				POI-02818 NIP-02-005, NCT00131313

Last Modified: 4/18/2008 First Published: 10/25/2004


2.		Phase I/II Study of Pentostatin and Donor Lymphocyte Infusion in Preventing Graft Rejection in Cancer Patients With Low or Falling Donor T-Cell Chimerism After Nonmyeloablative Allogeneic Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Under 75				NCI, Pharmaceutical / Industry				FHCRC-1825.00 SUPERGEN-FHCRC-1825.00, NCT00096161

First Published: 10/12/2007


3.		Phase I/II Study of Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone Hydrochloride in Patients With Previously Treated Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				MSKCC-05077 MSKCC IRB PRotocol #05-077, NCT00546377


4.		Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Pharmaceutical / Industry				OV06-001 NCT00709215

Last Modified: 10/1/2008 First Published: 9/1/2002


5.		Phase II Study of a Reduced-Intensity Preparative Regimen With Allogeneic Bone Marrow Transplantation in Patients With Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 to 70				NCI				ECOG-E1902 NCT00045305, E1902

Last Modified: 10/12/2008 First Published: 11/20/2003


6.		Phase II Study of Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				ECOG-2903 NCT00074282, E2903


7.		A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care, Treatment				Active				18 to 70				Other				0508000433 NCT00402714


8.		Alemtuzumab and Pentostatin In T-Cell Neoplasms

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				2004-0408 NCT00453193


9.		Phase II Trial of Pentostatin and Targeted Busulfan

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 to 70				Other				MCC15009 NCT00496340

First Published: 10/1/2007


10.		Phase II Study of Pentostatin, Cyclophosphamide, and Rituximab in Patients With Previously Untreated Intermediate- or High-Risk B-Cell Chronic Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				MSKCC-05051 MSKCC IRB 05-051, NCT00541034

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute